SCHEMBL14716698

SCHEMBL14716698

COc1cccc(-c2cn3cncc3c(N3CCOCC3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.50
TSHR P16473 3/20 0.50
CYP3A4 P08684 2/20 0.50
MAPK1 P28482 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2C9 P11712 1/20 0.50
HSD17B10 Q99714 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
STK4 Q13043 1/20 0.49
STK3 Q13188 1/20 0.49
LRRK2 Q5S007 1/20 0.49
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KMT2A Q03164 2/20 0.48
GAK O14976 1/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 1/20 0.48
CYP2D6 P10635 1/20 0.48
HIF1A Q16665 1/20 0.48
CLK4 Q9HAZ1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16881785 0.87 CYP1A2 (0.53) CYP1A2TSHRCYP3A4MAPK1CYP2C19
SCHEMBL16881780 0.86 PIK3CA (0.53) TSHRMAPK1HSD17B10L3MBTL1STK4
SCHEMBL14725959 0.84 PIK3CA (0.64) PIK3CAPIK3R1PRKDC
SCHEMBL14725977 0.80 PIK3CA (0.52) CYP1A2TSHRCYP3A4MAPK1CYP2C19
SCHEMBL632409 0.80 PIK3CA (0.74) CYP1A2TSHRCYP3A4MAPK1CYP2C19
SCHEMBL14725992 0.78 ALDH1A3 (0.54) HSD17B10MEN1ALDH1A1KMT2AUSP2
SCHEMBL14725961 0.77 PIK3CA (0.51) CYP1A2TSHRCYP3A4MAPK1CYP2C19
SCHEMBL16881772 0.76 PIK3CA (0.55) CYP1A2TSHRCYP3A4MAPK1CYP2C19
SCHEMBL14725956 0.75 PIK3CA (0.50) CYP1A2TSHRCYP3A4MAPK1CYP2C19
SCHEMBL20458862 0.75 CYP1A2 (0.51) CYP1A2TSHRCYP3A4MAPK1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526102-B1 Inhibitors of PI3 kinase FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) 2017-03-08 EP disclosed
EP-2526102-B1 Inhibitors of PI3 kinase FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) 2017-03-08 EP disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053371-A1 INHIBITORS OF PI3 KINASE PIK3CA, MTOR, PIK3C2A CYP1A2 1497/4885TSHR 2962/4885CYP3A4 869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.